Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review

1. World Health Organization . COVID-19 weekly epidemiological update, 15 August 2021. Geneva: WHO, 2021.
Google Scholar2. Miller, IF, Becker, AD, Grenfell, BT, et al. Disease and healthcare burden of COVID-19 in the United States. Nat Med 2020; 26: 1212–1217.
Google Scholar | Crossref | Medline3. Tamilselvan, T, Kumutha, T, Priyanka, M, et al. Incidence of Polypharmacy and Drug related problems among Geriatric patients in a Multispecialty hospital. Int J Res Develop Pharm Life Sci 2018; 7: 3055–3059.
Google Scholar4. Thorpe, A, Neal, D. Benign prostatic hyperplasia. Lancet 2003; 361: 1359–1367.
Google Scholar | Crossref | Medline5. Homma, Y, Gotoh, M, Kawauchi, A, et al. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol 2017; 24: 716–729.
Google Scholar | Crossref | Medline6. Fujita, K, Nonomura, N. Role of androgen receptor in prostate cancer: a review. World J Mens Health 2019; 37: 288–295.
Google Scholar | Crossref | Medline7. Liss, MA, Thompson, IM. Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies. Curr Opin Urol 2018; 28: 42–45.
Google Scholar | Crossref | Medline8. Ghazizadeh, Z, Majd, H, Richter, M, et al. Androgen regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men. bioRxiv 2020, https://www.biorxiv.org/content/10.1101/2020.05.12.091082v2
Google Scholar9. Goren, A, Vaño-Galván, S, Wambier, CG, et al. A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain–a potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol 2020; 19: 1545–1547.
Google Scholar | Crossref | Medline10. Wiersinga, WJ, Rhodes, A, Cheng, AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324: 782–793.
Google Scholar | Crossref | Medline11. Wambier, CG, Goren, A, Vaño-Galván, S, et al. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res 2020; 81: 771–776.
Google Scholar | Crossref | Medline12. McCoy, J, Cadegiani, FA, Wambier, CG, et al. 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. J Eur Acad Dermatol Venereol 2021; 35: e243–e246.
Google Scholar | Crossref | Medline13. Cadegiani, FA, McCoy, J, Wambier, CG, et al. 5-alpha-reductase inhibitors reduce remission time of COVID-19: results from a randomized double blind placebo controlled interventional trial in 130 SARS-CoV-2 positive men. medRxiv 2020, https://www.medrxiv.org/content/10.1101/2020.11.16.20232512v1
Google Scholar14. Adamowicz, J, Juszczak, K, Drewa, T. May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications. Med Hypotheses 2020; 140: 109751.
Google Scholar | Crossref | Medline15. Lokeshwar, SD, Harper, BT, Webb, E, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol 2019; 8: 529–539.
Google Scholar | Crossref | Medline16. Lepor, H, Kazzazi, A, Djavan, B. α-Blockers for benign prostatic hyperplasia: the new era. Curr Opin Urol 2012; 22: 7–15.
Google Scholar | Crossref | Medline | ISI17. Chung, MS, Yoon, BI, Lee, SH. Clinical efficacy and safety of naftopidil treatment for patients with benign prostatic hyperplasia and hypertension: a prospective, open-label study. Yonsei Med J 2017; 58: 800–806.
Google Scholar | Crossref | Medline18. Konig, MF, Powell, M, Staedtke, V, et al. Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. J Clin Invest 2020; 130: 3345–3347.
Google Scholar | Crossref | Medline19. Konig, MF, Powell, M, Staedtke, V, et al. Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome. medRxiv 2020, https://www.medrxiv.org/content/10.1101/2020.04.02.20051565v2
Google Scholar20. Yamamoto, V, Bolanos, JF, Fiallos, J, et al. COVID-19: review of a 21st century pandemic from etiology to neuro-psychiatric implications. J Alzheimers Dis 2020; 77: 459–504.
Google Scholar | Crossref | Medline21. Vogelstein, JT, Powell, M, Koenecke, A, et al. Alpha-1 adrenergic receptor antagonists for preventing acute respiratory distress syndrome and death from cytokine storm syndrome. arXiv 2004.10117, https://arxiv.org/abs/2004.10117
Google Scholar22. Chen, L, Shi, G-r, Huang Li, Y, et al. Male sexual dysfunction: a review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention. Biomed Pharmacother 2019; 112: 108585.
Google Scholar | Crossref | Medline23. Chokka, PR, Hankey, JR. Assessment and management of sexual dysfunction in the context of depression. Ther Adv Psychopharmacol 2018; 8: 13–23.
Google Scholar | SAGE Journals | ISI24. Mondaini, N . Phosphodiesterase type 5 inhibitors and COVID-19: are they useful in disease management? World J Mens Health 2020; 38: 254–255.
Google Scholar | Crossref | Medline25. Giorgi, M, Cardarelli, S, Ragusa, F, et al. Phosphodiesterase inhibitors: could they be beneficial for the treatment of COVID-19? Int J Mol Sci 2020; 21: 5338.
Google Scholar | Crossref26. Reinert, JP, Reinert, NJ. The role of phosphodiesterase-5 inhibitors in COVID-19: an exploration of literature from similar pathologies. J Intensive Care Med 2021; 36: 3–8.
Google Scholar | SAGE Journals | ISI27. Rogosnitzky, M, Berkowitz, E, Jadad, AR. Delivering benefits at speed through real-world repurposing of off-patent drugs: the COVID-19 pandemic as a case in point. JMIR Public Health Surveill 2020; 6: e19199.
Google Scholar | Crossref | Medline28. Chinello, P, Cicalini, S, Pichini, S, et al. Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors. Curr HIV Res 2012; 10: 162–164.
Google Scholar | Crossref | Medline29. Ciracì, R, Tirone, G, Scaglione, F. The impact of drug–drug interactions on pulmonary arterial hypertension therapy. Pulm Pharmacol Ther 2014; 28: 1–8.
Google Scholar | Crossref | Medline | ISI30. Liu, H, Zhang, M, Huang, M, et al. Comparative efficacy and safety of drug treatment for premature ejaculation: a systemic review and Bayesian network meta-analysis. Andrologia 2020; 52: e13806.
Google Scholar | Crossref | Medline31. Hamed, MGM, Hagag, RS. The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients. Med Hypotheses 2020; 144: 110140.
Google Scholar | Crossref | Medline32. Hoertel, N, Rico, MS, Vernet, R, et al. Association between SSRI antidepressant use and reduced risk of intubation or death in hospitalized patients with coronavirus disease 2019: a multicenter retrospective observational study. medRxiv 2020, https://www.medrxiv.org/content/10.1101/2020.07.09.20143339v2
Google Scholar33. Creeden, J, Imami, AS, Eby, HM, et al. Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection. Biomed Pharmacother 2021; 138: 111437.
Google Scholar | Crossref | Medline34. Lenze, EJ, Mattar, C, Zorumski, CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 2020; 324: 2292–2300.
Google Scholar | Crossref | Medline35. Ishima, T, Fujita, Y, Hashimoto, K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol 2014; 727: 167–173.
Google Scholar | Crossref | Medline36. Baumeister, D, Ciufolini, S, Mondelli, V. Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment. Psychopharmacology 2016; 233: 1575–1589.
Google Scholar | Crossref | Medline37. Kostadinov, I, Delev, D, Petrova, A, et al. Study on anti-inflammatory and immunomodulatory effects of clomipramine in carrageenan-and lipopolysaccharide-induced rat models of inflammation. Biotechnol Biotechnol Equip 2014; 28: 552–558.
Google Scholar | Crossref | Medline38. Nobile, B, Durand, M, Olié, E, et al. Clomipramine could be useful in preventing neurological complications of SARS-CoV-2 infection. J Neuroimmune Pharmacol 2020; 15: 347–348.
Google Scholar | Crossref | Medline39. Javelot, H, Weiner, L, Petrignet, J, et al. Psychoactive compounds as multifactorial protection factors against COVID-19. Ir J Med Sci 2021; 190: 849–850.
Google Scholar | Crossref | Medline40. Mohebbi, N, Talebi, A, Moghadamnia, M, et al. Drug interactions of psychiatric and COVID-19 medications. Basic Clin Neurosci 2020; 11: 185–200.
Google Scholar | Medline41. Fakhr Yasseri, A, Aghamir, SMK. Urinary stone management during the COVID-19 pandemic: a suggested approach and review of literature. Ther Adv Urol 2020; 12: 1–5.
Google Scholar | SAGE Journals42. Jung, H, Andonian, S, Assimos, D, et al. Urolithiasis: evaluation, dietary factors, and medical management: an update of the 2014 SIU-ICUD international consultation on stone disease. World J Urol 2017; 35: 1331–1340.
Google Scholar | Crossref | Medline43. Vosu, J, Britton, P, Howard-Jones, A, et al. Is the risk of ibuprofen or other non-steroidal anti-inflammatory drugs increased in COVID-19. J Paediatr Child Health 2020; 56: 1645–1646.
Google Scholar | Crossref | Medline44. Moore, N, Carleton, B, Blin, P, et al. Does ibuprofen worsen COVID-19? Cham: Springer, 2020.
Google Scholar45. Vaja, R, Chan, JSK, Ferreira, P, et al. The COVID-19 ibuprofen controversy: a systematic review of NSAIDs in adult acute lower respiratory tract infections. Br J Clin Pharmacol 2021; 87: 776–784.
Google Scholar | Crossref | Medline46. Day, M . COVID-19: European drugs agency to review safety of ibuprofen. BMJ 2020; 368: m1168.
Google Scholar | Crossref | Medline47. Bryan, J . How the discovery of ibuprofen helped pave the way for other NSAIDs. Evaluation 2020; 14: 34.
Google Scholar48. Cumhur Cure, M, Kucuk, A, Cure, E. NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection. Therapie 2020; 75: 387–388.
Google Scholar | Crossref | Medline49. Schüchen, RH, Mücke, M, Marinova, M, et al. Systematic review and meta-analysis on non-opioid analgesics in palliative medicine. J Cachexia Sarcopenia Muscle 2018; 9: 1235–1254.
Google Scholar | Crossref | Medline50. Davis, CS, Lieberman, AJ, Hernandez-Delgado, H, et al. Laws limiting the prescribing or dispensing of opioids for acute pain in the United States: a national systematic legal review. Drug and Alcohol Dependence 2019; 194: 166–172.
Google Scholar | Crossref | Medline51. Ataei, M, Shirazi, FM, Lamarine, RJ, et al. A double-edged sword of using opioids and COVID-19: a toxicological view. Subst Abuse Treat Pr 2020; 15: 1–4.
Google Scholar | Medline52. El-Tallawy, SN, Nalamasu, R, Pergolizzi, JV, et al. Pain management during the COVID-19 pandemic. Pain Ther 2020; 9: 453–466.
Google Scholar | Crossref | Medline53. Abbasinazari, M, Azizian, H. Probable QT prolongation between chloroquine/hydroxychloroquine in treatment of COVID-19 infection and other medications. J Cell Mol Anesth 2020; 5: 212–213.
Google Scholar54. Gandolfini, I, Delsante, M, Fiaccadori, E, et al. COVID-19 in kidney transplant recipients. Am J Transplant 2020; 20: 1941–1943.

留言 (0)

沒有登入
gif